172 related articles for article (PubMed ID: 8648209)
1. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.
Jacobsen H; Hänggi M; Ott M; Duncan IB; Owen S; Andreoni M; Vella S; Mous J
J Infect Dis; 1996 Jun; 173(6):1379-87. PubMed ID: 8648209
[TBL] [Abstract][Full Text] [Related]
2. Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.
Jacobsen H; Haenggi M; Ott M; Duncan IB; Andreoni M; Vella S; Mous J
Antiviral Res; 1996 Jan; 29(1):95-7. PubMed ID: 8721556
[TBL] [Abstract][Full Text] [Related]
3. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.
Jacobsen H; Yasargil K; Winslow DL; Craig JC; Kröhn A; Duncan IB; Mous J
Virology; 1995 Jan; 206(1):527-34. PubMed ID: 7831807
[TBL] [Abstract][Full Text] [Related]
4. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.
Race E; Gilbert SM; Sheldon JG; Rose JS; Moffatt AR; Sitbon G; Dissanayeke SR; Cammack N; Duncan IB
AIDS; 1998 Aug; 12(12):1465-74. PubMed ID: 9727567
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
[TBL] [Abstract][Full Text] [Related]
6. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.
Eberle J; Bechowsky B; Rose D; Hauser U; von der Helm K; Gürtler L; Nitschko H
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):671-6. PubMed ID: 7576926
[TBL] [Abstract][Full Text] [Related]
7. Saquinavir: an HIV proteinase inhibitor.
Bragman K
Adv Exp Med Biol; 1996; 394():305-17. PubMed ID: 8815695
[No Abstract] [Full Text] [Related]
8. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir.
Ives KJ; Jacobsen H; Galpin SA; Garaev MM; Dorrell L; Mous J; Bragman K; Weber JN
J Antimicrob Chemother; 1997 Jun; 39(6):771-9. PubMed ID: 9222047
[TBL] [Abstract][Full Text] [Related]
9. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
[TBL] [Abstract][Full Text] [Related]
10. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors.
Roberts NA
AIDS; 1995 Dec; 9 Suppl 2():27-S32. PubMed ID: 8775804
[TBL] [Abstract][Full Text] [Related]
11. Conference highlight.
J Int Assoc Physicians AIDS Care; 1995 Aug; 1(7):26. PubMed ID: 11362749
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with saquinavir.
Vella S
AIDS; 1995 Dec; 9 Suppl 2():S21-S25. PubMed ID: 8775803
[TBL] [Abstract][Full Text] [Related]
13. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity.
Vella S; Galluzzo C; Giannini G; Pirillo MF; Duncan I; Jacobsen H; Andreoni M; Sarmati L; Ercoli L
Antiviral Res; 1996 Jan; 29(1):91-3. PubMed ID: 8721555
[No Abstract] [Full Text] [Related]
14. Saquinavir thwarts resistance.
AIDS Alert; 1995 Oct; 10(10):123. PubMed ID: 11362782
[TBL] [Abstract][Full Text] [Related]
15. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
[TBL] [Abstract][Full Text] [Related]
16. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.
Race E; Dam E; Obry V; Paulous S; Clavel F
AIDS; 1999 Oct; 13(15):2061-8. PubMed ID: 10546858
[TBL] [Abstract][Full Text] [Related]
17. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase.
Turriziani O; Antonelli G; Jacobsen H; Mous J; Riva E; Pistello M; Dianzani F
Acta Virol; 1994 Oct; 38(5):297-8. PubMed ID: 7726006
[TBL] [Abstract][Full Text] [Related]
18. HIV therapy advances. Update on a proteinase inhibitor.
Vella S
AIDS; 1994 Sep; 8 Suppl 3():S25-9. PubMed ID: 7840913
[TBL] [Abstract][Full Text] [Related]
19. Protease inhibitors and prevention of cross resistance.
Levin J
AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
[TBL] [Abstract][Full Text] [Related]
20. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
